Inventory

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Inventory

7. Inventory

All of the Company’s inventory relates to the manufacturing of TAZVERIK. The following table sets forth the Company’s inventory as of March 31, 2022 and December 31, 2021:

	March 31, 2022		December 31, 2021
	(In thousands)
Raw materials	$	2,059	$	3,227
Work in process		19,402		13,748
Finished goods		1,362		1,710
Total	$	22,823	$	18,685
Balance sheet classification
Inventory	$	4,594	$	3,216
Restricted cash and other assets		18,229		15,469
Total	$	22,823	$	18,685

The Company’s active pharmaceutical ingredient has a long shelf life and the Company’s finished drug product has a three-year expiry, however the realizability of the inventory is subject to forecasted future sales of TAZVERIK. The Company’s forecasted sales currently support the realizability of the Company’s inventory but are uncertain and could change in the future, which would require the Company to write down the value of such inventory.

As of March 31, 2022 the Company has not capitalized inventory costs related to its other drug development programs.